Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MRKR 
Marker Therapeutics Inc (MRKR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/10/2025: MRKR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -16.35% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.07M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 2 | Beta 1.47 | 52 Weeks Range 0.81 - 5.95 | Updated Date 10/12/2025 |
52 Weeks Range 0.81 - 5.95 | Updated Date 10/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.35 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -271.11% | Operating Margin (TTM) -494.79% |
Management Effectiveness
Return on Assets (TTM) -69.39% | Return on Equity (TTM) -144.68% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1312437 | Price to Sales(TTM) 2.43 |
Enterprise Value 1312437 | Price to Sales(TTM) 2.43 | ||
Enterprise Value to Revenue 0.2 | Enterprise Value to EBITDA -0.22 | Shares Outstanding 12938910 | Shares Floating 10386322 |
Shares Outstanding 12938910 | Shares Floating 10386322 | ||
Percent Insiders 7.08 | Percent Institutions 26.37 |
Upturn AI SWOT
Marker Therapeutics Inc
Company Overview
History and Background
Marker Therapeutics Inc., formerly TapImmune Inc., was founded in 2008. It focuses on developing cell-based immunotherapies for the treatment of hematological malignancies and solid tumors.
Core Business Areas
- T-Cell Immunotherapies: Developing multi-tumor associated antigen (TAA) specific T-cell therapies for cancer.
Leadership and Structure
The leadership team includes Juan F. Vera, M.D., as President and CEO. The organizational structure comprises research and development, clinical operations, and administrative functions.
Top Products and Market Share
Key Offerings
- MT-401: A multi-TAA specific T-cell therapy targeting hematological malignancies. Currently in clinical trials. No significant market share or revenue currently. Competitors: Novartis (Kymriah), Gilead (Yescarta), Bristol Myers Squibb (Breyanzi).
- MT-601: A multi-TAA specific T-cell therapy targeting solid tumors. Currently in clinical trials. No significant market share or revenue currently. Competitors: Many companies in the solid tumor immunotherapy space, including Roche, Merck, and AstraZeneca.
Market Dynamics
Industry Overview
The cell-based immunotherapy market is rapidly growing, driven by advancements in cancer research and treatment. It's characterized by high competition and significant investment in research and development.
Positioning
Marker Therapeutics is a smaller player in the immunotherapy market, focusing on multi-TAA specific T-cell therapies. Its competitive advantage lies in its specific approach and target antigens.
Total Addressable Market (TAM)
The global cancer immunotherapy market is projected to reach hundreds of billions of dollars. Marker Therapeutics is positioned to capture a portion of this market with successful clinical trials and approvals.
Upturn SWOT Analysis
Strengths
- Proprietary multi-TAA specific T-cell therapy platform
- Potential for broad applicability across cancer types
- Experienced leadership team
Weaknesses
- Limited financial resources
- Early-stage clinical development
- Dependence on successful clinical trial outcomes
Opportunities
- Positive clinical trial results leading to partnerships or acquisitions
- Expansion of TAA targets
- Collaboration with larger pharmaceutical companies
Threats
- Clinical trial failures
- Competition from established immunotherapy companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- NVS
- GILD
- BMY
- MRK
- PFE
- AZN
- RHHBY
- JNJ
Competitive Landscape
Marker Therapeutics faces intense competition from larger, well-funded pharmaceutical companies. It must demonstrate superior efficacy and safety to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Growth is dependent on progress in clinical trials and obtaining funding.
Future Projections: Future growth depends on positive clinical trial data and potential regulatory approval. Analyst estimates are dependent on clinical progress.
Recent Initiatives: Focus on advancing MT-401 and MT-601 through clinical trials.
Summary
Marker Therapeutics is a high-risk, high-reward clinical-stage biotechnology company focused on developing multi-TAA specific T-cell immunotherapies. Its success depends on positive clinical trial results and securing funding. The company faces significant competition and regulatory hurdles, but potential exists if their therapies prove effective and safe.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investing in biotechnology companies involves significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Marker Therapeutics Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2014-03-25 | Co-Founder, CEO, President, Treasurer, Secretary & Director Dr. Juan F. Vera M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://markertherapeutics.com |
Full time employees 5 | Website https://markertherapeutics.com | ||
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.